In SENDAI, Japan, RevolKa Ltd. (RevolKa), a venture-backed biotech company, has introduced 'RevoAb™', a new contract research service utilizing their advanced AI-driven protein engineering platform, aiProtein®. This service focuses on enhancing antibodies by refining physicochemical characteristics without compromising antigen binding affinity. Since December 2023, RevolKa has been providing contract research services for antibody engineering through aiProtein®.